Martin Gerstel
In addition to serving as Director of Itamar Medical, Mr. Gerstel is chairman of Compugen (NASDAQ and TASE: CGEN), Evogene (NASDAQ and TASE:EVGN), and Keddem Bioscience. Prior to relocating to Israel in 1994, Mr. Gerstel was the Co-Chairman and CEO of ALZA Corporation (sold to Johnson & Johnson). Mr. Gerstel currently serves as a director of YEDA (the technology transfer company for the Weizmann Institute of Science), Yissum (the technology transfer company of the Hebrew University) and the Foundation for the US National Medals of Science and Technology. He is a member of the board of governors and the executive committee of the Weizmann Institute of Science and the board of governors of the Hebrew University, and is an advisor to the Burrill Life Science Funds and to the board of the Israel-U.S. BiNational Industrial Research and Development (“BIRD”) Foundation. Mr. Gerstel is a graduate of Yale University and Stanford Graduate School of Business.